Treatment of HIV infection with raltegravir
- PMID: 19385721
- DOI: 10.1517/14656560902911488
Treatment of HIV infection with raltegravir
Abstract
Background: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus.
Objective: To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability.
Methods: Data from pharmacokinetic, Phase II and III clinical trials were reviewed.
Results/conclusions: Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naïve and -experienced patients.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical